Gary A. Lyons - 15 May 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Director
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
15 May 2025
Net transactions value
$0
Form type
4
Filing time
16 May 2025, 19:00:12 UTC
Previous filing
04 Oct 2024
Next filing
22 May 2025
SEC
View on sec.gov

Key filing fact

Gary A. Lyons filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 16 May 2025.

Key facts

  • This page summarizes Gary A. Lyons's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 16 May 2025, 19:00.

Change

  • Previous filing in this sequence was filed on 04 Oct 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001123343 Primary reporting owner

LYONS GARY A

Relationship
Director
Address
C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Signature date
16 May 2025

Transactions Table

TVTX transaction

Common Stock

Award

Transaction value
$0
Shares
+6,500
Change %
+13%
Price
$0.000000
Shares after
57,500
Date
15 May 2025
Ownership
Direct
Footnotes
F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

TVTX transaction Derivative

Stock option (right to buy)

Award

Transaction value
$0
Shares
+19,500
Change %
Price
$0.000000
Shares after
19,500
Date
15 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
19,500
Exercise price
$21.15
Footnotes
F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
F2 The equity award vests over a one year period.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .